An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety
Open Access
- 2 April 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 19 (4) , 325-335
Abstract
Introduction In the 20 years since its introduction to the palette of intravenous hemodynamic therapies, the inodilator levosimendan has established itself as a valuable asset for the management of acute decompensated heart failure. Its pharmacology is notable for delivering inotropy via calcium sensitization without an increase in myocardial oxygen consumption. Areas covered Experience with levosimendan has led to its applications expanding into perioperative hemodynamic support and various critical care settings, as well as an array of situations associated with acutely decompensated heart failure, such as right ventricular failure, cardiogenic shock with multi-organ dysfunction, and cardio-renal syndrome. Evidence suggests that levosimendan may be preferable to milrinone for patients in cardiogenic shock after cardiac surgery or for weaning from extracorporeal life support and may be superior to dobutamine in terms of short-term survival, especially in patients on beta-blockers. Positive effects on kidney function have been noted, further differentiating levosimendan from catecholamines and phosphodiesterase inhibitors. Expert opinion Levosimendan can be a valuable resource in the treatment of acute cardiac dysfunction, especially in the presence of beta-blockers or ischemic cardiomyopathy. When attention is given to avoiding or correcting hypovolemia and hypokalemia, an early use of the drug in the treatment algorithm is preferred.Keywords
This publication has 108 references indexed in Scilit:
- Levosimendan: A Cardiovascular Drug to Prevent Liver Ischemia-Reperfusion Injury?PLOS ONE, 2013
- Renal Effects of Levosimendan: A Consensus ReportCardiovascular Drugs and Therapy, 2013
- Modulation of Programmed Forms of Cell Death by Intracoronary Levosimendan During Regional Myocardial Ischemia in Anesthetized PigsCardiovascular Drugs and Therapy, 2010
- Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsEuropean Heart Journal, 2009
- Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVEEuropean Journal of Heart Failure, 2009
- Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATPchannelBritish Journal of Pharmacology, 2009
- A role for the RISK pathway and KATPchannels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heartBritish Journal of Pharmacology, 2008
- Levosimendan Improves Renal Function in Patients with Acute Decompensated Heart Failure: Comparison with DobutamineCardiovascular Drugs and Therapy, 2007
- The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass graftingCritical Care, 2007
- Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp ratsBritish Journal of Pharmacology, 2007